APA (7th ed.) Citation

Suzuki, T., Maruyama, D., Machida, R., Ito, Y., Kataoka, K., & Nagai, H. (2023). 352TiP Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study). Annals of Oncology, 34, S1606. https://doi.org/10.1016/j.annonc.2023.10.734

Chicago Style (17th ed.) Citation

Suzuki, T., D. Maruyama, R. Machida, Y. Ito, K. Kataoka, and H. Nagai. "352TiP Randomized Phase III Study of Daratumumab (D) Versus Bortezomib Plus D as a Maintenance Therapy After D-MPB for Elderly or Non-elderly Patients Refusing Transplant with Untreated Multiple Myeloma (JCOG1911, B-DASH Study)." Annals of Oncology 34 (2023): S1606. https://doi.org/10.1016/j.annonc.2023.10.734.

MLA (9th ed.) Citation

Suzuki, T., et al. "352TiP Randomized Phase III Study of Daratumumab (D) Versus Bortezomib Plus D as a Maintenance Therapy After D-MPB for Elderly or Non-elderly Patients Refusing Transplant with Untreated Multiple Myeloma (JCOG1911, B-DASH Study)." Annals of Oncology, vol. 34, 2023, p. S1606, https://doi.org/10.1016/j.annonc.2023.10.734.